Skip to main content
. 2019 Aug 8;7:213. doi: 10.1186/s40425-019-0689-7

Fig. 1.

Fig. 1

a. Clinical photographs of patient 4. b. PET imaging showing the site of progression of patient 4 before and after switching therapy to Nivolumab/Pembrolizumab. c. Clinical photographs of patient 6